Alvotech upgraded by Citigroup with a new price target
$ALVO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Citigroup upgraded Alvotech from Sell to Neutral and set a new price target of $10.00 from $5.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2025 | $5.00 | Underweight | Barclays |
| 11/4/2025 | $8.00 | Buy → Hold | Deutsche Bank |
| 10/14/2025 | $14.00 | Equal-Weight → Overweight | Morgan Stanley |
| 9/23/2025 | $14.00 | Hold → Buy | Deutsche Bank |
| 2/14/2025 | $18.00 | Buy | UBS |
| 1/29/2024 | $10.00 → $17.00 | Equal Weight → Overweight | Barclays |
| 10/20/2023 | $5.00 → $10.00 | Sell → Neutral | Citigroup |
| 9/21/2023 | $10.00 | Equal Weight | Barclays |
Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-2) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:
Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-1) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:
Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-3) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:
- Róbert Wessman to continue serving as Executive Chairman in full-time capacity - Lisa Graver appointed Chief Executive Officer REYKJAVIK, Iceland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced key senior leadership changes following a planned succession process. Founder Róbert Wessman, who has served as Chairman since the company's inception in 2013 and Chief Executive Officer since 2023, will transition out of the CEO role at the end of the first quarter of 2026. He will continue to serve as Executive Chairman in a full-time capac
The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Alvotech ("Alvotech" or the "Company") (NASDAQ:ALVO) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On November 3, 2025, the Company received a complete response letter ("CRL") from the FDA for its biologics license application for AVT05. The CRL relates to a failed facility inspection which occurred in July 2025. On this news, the price of Alvotech shares declined by $2.62 per share, or approximately 34.25%, from $7.65 per share on O
USD 100 million senior term loan facility with a 2-year maturityStrengthens liquidity to support execution across Alvotech's R&D pipeline and global product launches through 2026Led by GoldenTree Asset Management REYKJAVIK, Iceland, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a USD 100 million senior term loan facility with maturity in December 2027 aimed at strengthening liquidity and supporting the execution of Alvotech's strategic priorities in 2026. "This USD 100 million financing underscores the long-term commitment of our fina
Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue increased by 85%, to $237 million in the first nine months compared to the same period last yearLicense and other revenue decreased by 13% to $182 million, compared to the same period last yearAdjusted EBITDA in the first nine months of the year was $68 million, a 21% decrease from the same period last year, driven by higher R&D investments to accelerate pipeline expansion and lower licensing revenues in the period. Phasing of revenues in 2024 resulted in Q2 being the best quarter of the year, while Q4 of is expected to be the best quarter of 2025
REYKJAVIK, Iceland, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first nine months of the year ended September 30, 2025, after U.S. markets close on Wednesday, November 12, 2025. Alvotech will also conduct a conference call to present the financial results on Thursday November 13, 2025, at 8:00 am EST (13:00 GMT, 14:00 CET). On the call, management will provide a business update, including the status of pending approvals in the U.S. and Europe. A call in number is available for participants in the
REYKJAVIK, Iceland, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first half of the year ended June 30, 2025, after U.S. markets close on Wednesday, August 13, 2025. Alvotech will also conduct a conference call to present the financial results and recent business highlights on Thursday, August 14, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET). Live audio of the conference call will be webcast and available on Alvotech's investor portal. Information on how to access the webcast or particip
6-K - Alvotech (0001898416) (Filer)
6-K - Alvotech (0001898416) (Filer)
6-K - Alvotech (0001898416) (Filer)
Barclays initiated coverage of Alvotech with a rating of Underweight and set a new price target of $5.00
Deutsche Bank downgraded Alvotech from Buy to Hold and set a new price target of $8.00
Morgan Stanley upgraded Alvotech from Equal-Weight to Overweight and set a new price target of $14.00
- Róbert Wessman to continue serving as Executive Chairman in full-time capacity - Lisa Graver appointed Chief Executive Officer REYKJAVIK, Iceland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced key senior leadership changes following a planned succession process. Founder Róbert Wessman, who has served as Chairman since the company's inception in 2013 and Chief Executive Officer since 2023, will transition out of the CEO role at the end of the first quarter of 2026. He will continue to serve as Executive Chairman in a full-time capac
REYKJAVIK, ICELAND (August 20, 2025) — Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Patrik Ling has joined the company as VP Investor Relations Scandinavia, based in Stockholm. Patrik Ling has more than 25 years of experience in the life-science industry. Most recently he served as Senior Equity Analyst at the investment bank DNB Carnegie, covering life science companies, including Alvotech. He began his career in marketing and sales of pharmaceuticals, before transitioning to the financial sector, where he was a portfolio manager and equity analyst focusing on the life-s
REYKJAVIK, ICELAND (July 10, 2025) — Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Linda Jónsdóttir as Chief Financial Officer (CFO). Linda is a highly experienced international executive with a strong background in finance and corporate leadership. She has held senior roles across a range of industries, including banking, food technology, transportation, and healthcare. Linda will be based in Iceland. Joel Morales, who has served as CFO of Alvotech since 2020, based in the U.S., has decided to step down to spend more time in the U.S. and prioritize time with
SC 13G/A - Alvotech (0001898416) (Subject)
SC 13D/A - Alvotech (0001898416) (Subject)
SC 13G/A - Alvotech (0001898416) (Subject)